In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
It’s more than just code. Scientists have found a way to "dial" the hidden personalities of AI, from conspiracy theorists to ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results